Phase I and pharmacokinetic study of romidepsin in patients with cancer and hepatic dysfunction: A national cancer institute organ dysfunction working group study
RM Connolly, E Laille, U Vaishampayan, V Chung… - Clinical Cancer …, 2020 - AACR
Purpose: Romidepsin dosing recommendations for patients with malignancy and varying
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group …
RM Connolly, E Laille… - … : an official journal …, 2020 - pubmed.ncbi.nlm.nih.gov
Purpose Romidepsin dosing recommendations for patients with malignancy and varying
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …
Phase i and pharmacokinetic study of romidepsin in patients with cancer and hepatic dysfunction: A national cancer institute organ dysfunction working group study
ETCTN-9008 Study Team - Clinical Cancer Research, 2020 - jhu.pure.elsevier.com
Purpose: Romidepsin dosing recommendations for patients with malignancy and varying
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …
Phase i and pharmacokinetic study of romidepsin in patients with cancer and hepatic dysfunction: A national cancer institute organ dysfunction working group study
ETCTN-9008 Study Team - Clinical Cancer Research, 2020 - pure.johnshopkins.edu
Purpose: Romidepsin dosing recommendations for patients with malignancy and varying
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …
[PDF][PDF] Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working …
RM Connolly, E Laille, U Vaishampayan… - Clin Cancer …, 2020 - researchgate.net
Purpose: Romidepsin dosing recommendations for patients with malignancy and varying
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …
Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working Group …
RM Connolly, E Laille, U Vaishampayan… - … Cancer Research: an …, 2020 - europepmc.org
Purpose Romidepsin dosing recommendations for patients with malignancy and varying
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …
Phase i and pharmacokinetic study of romidepsin in patients with cancer and hepatic dysfunction: A national cancer institute organ dysfunction working group study
ETCTN-9008 Study Team - Clinical Cancer Research, 2020 - ohsu.pure.elsevier.com
Purpose: Romidepsin dosing recommendations for patients with malignancy and varying
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …
Phase i and pharmacokinetic study of romidepsin in patients with cancer and hepatic dysfunction: A national cancer institute organ dysfunction working group study
ETCTN-9008 Study Team - Clinical Cancer Research, 2020 - ohsu.elsevierpure.com
Purpose: Romidepsin dosing recommendations for patients with malignancy and varying
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …
[HTML][HTML] Phase I and Pharmacokinetic Study of Romidepsin in Patients with Cancer and Hepatic Dysfunction: A National Cancer Institute Organ Dysfunction Working …
RM Connolly, E Laille, U Vaishampayan… - … cancer research: an …, 2020 - ncbi.nlm.nih.gov
Purpose: Romidepsin dosing recommendations for patients with malignancy and varying
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …
degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell …